Clinical factors associated with death during hospitalization in parvovirus infection dogs

Main Article Content

Jutapoln Sunghan
Areerath Akatvipat
Jennifer Granick
Phongsakorn Chuammitri
Sukolrat Boonyayatra

Abstract

Canine parvovirus (CPV) is a highly spreadable virus that causes significant mortality and morbidity especially in young dogs. The outcome of treatment may different depending on several factors. The aim of this study was to evaluate the association of clinical factors and the death in naturally acquired parvovirus infection dogs during hospitalization at the small animal teaching hospital. Forty-six dogs, with fecal polymerase chain reaction confirmed CPV, were studied during June 2016 to May 2017. All dogs received the standard treatment; intravenous fluids, broad spectrum antibiotics, antiemetic therapy, and deworming. The total clinical scores, routine blood test and hemoculture were examined at D 0, 3, 5, 7 of hospitalization. Three factors associated with mortality were: predisposing breed (OR = 0.190, 95% CI = 0.095–0.383, p < 0.001), small breed (OR = 0.168, 95% CI = 0.076–0.374, p < 0.001) and light weight (OR = 1.093, 95% CI = 1.005–1.189, p < 0.05). The overall mortality rate was 32.60% (15/46). The median time of hospitalization in survivor (n= 31) was 5 days. The mortality rate was highest on the Day 3 (n= 12). Although viral infection and using intravenously antibiotics, the bacteremia can be found (15.66%, 13 from 83 hemoculture samples). In conclusion, the CPV dog with predisposing breed, small breed or light weight had a significantly increasing risk with death. The first three day of hospitalization is a critical period and need more attention. The impact of sepsis and opportunistic bacteremia requires further studies. 

Article Details

How to Cite
Sunghan, J., Akatvipat, A., Granick, J., Chuammitri, P., & Boonyayatra, S. (2019). Clinical factors associated with death during hospitalization in parvovirus infection dogs. Veterinary Integrative Sciences, 17(2), 171–180. Retrieved from https://he02.tci-thaijo.org/index.php/vis/article/view/181497
Section
Research Articles

References

Arslan, H.H., Aksu, D.S., Terzi, G., Nisbet, C., 2012. Therapeutic effects of probiotic bacteria in parvoviral enteritis in dogs. Revue De Medecine Veterinaire 163, 55-59.
Brunner CJ, S.L., 1985. Canine parvovirus infection: effects on the immune system and factors that predispose to severe disease. Comp Cont Ed Pract Vet 7, 979-988.
Carla Miranda, J.C., Colin R.Parrish, GertrudeThompson, 2015. Factors affecting the occurrence of canine parvovirus in dogs. Veterinary Microbiology 180, 59-64.
Carr-Smith S, M.D., Swango LJ, 1997. Canine parvovirus: Part 1. Pathogenesis and Vaccination. Comp Cont Ed Pract Vet 19, 125-133.
Day, M.J., 1999. Possible immunodeficiency in related rottweiler dogs. J Small Anim Pract 40, 561-568.
Glickman, L.T., Domanski, L.M., Patronek, G.J., Visintainer, F., 1985. Breed-related risk factors for canine parvovirus enteritis. J Am Vet Med Assoc 187, 589-594.
Goddard, A., Leisewitz, A.L., 2010. Canine parvovirus. Vet Clin North Am Small Anim Pract 40, 1041-1053.
Goddard, A., Leisewitz, A.L., Christopher, M.M., Duncan, N.M., Becker, P.J., 2008. Prognostic usefulness of blood leukocyte changes in canine parvoviral enteritis. J Vet Intern Med 22, 309-316.
Greene, C.E., 2012. Infectious disease of the dog and cat, 4 Edition. ELSEVIER SAUDERS, St. Louis, Missouri.
Houston, D.M., Ribble, C.S., Head, L.L., 1996. Risk factors associated with parvovirus enteritis in dogs: 283 cases (1982-1991). J Am Vet Med Assoc 208, 542-546.
Iris, K., Leontides, L.S., Mylonakis, M.E., Adamama-Moraitou, K., Rallis, T., Koutinas, A.F., 2010. Factors affecting the occurrence, duration of hospitalization and final outcome in canine parvovirus infection. Res Vet Sci 89, 174-178.
Nandi, S., Kumar, M., 2010. Canine parvovirus: current perspective. Indian J Virol 21, 31-44.
Njenga MK, N.P., Buoro IBJ, Gathumbi PK. , 1990. Effectiveness of fluids and antibiotics as supportive therapy of canine parvovirus-2 enteritis in puppies. Bull Anim Health Prod Afr J Infect Dis 38, 379-389.
Otto, C.M., Drobatz, K.J., Soter, C., 1997. Endotoxemia and tumor necrosis factor activity in dogs with naturally occurring parvoviral enteritis. J Vet Intern Med 11, 65-70.
Otto, C.M., Jackson, C.B., Rogell, E.J., Prior, R.B., Ammons, W.S., 2001. Recombinant bactericidal/permeability-increasing protein (rBPI21) for treatment of parvovirus enteritis: a randomized, double-blinded, placebo-controlled trial. J Vet Intern Med 15, 355-360.
Parrish, C.R., 1999. Host range relationships and the evolution of canine parvovirus. Vet Microbiol 69, 29-40.
Pollock, R.V., Coyne, M.J., 1993. Canine parvovirus. Vet Clin North Am Small Anim Pract 23, 555-568.
Potgieter, L.N., Jones, J.B., Patton, C.S., Webb-Martin, T.A., 1981. Experimental parvovirus infection in dogs. Can J Comp Med 45, 212-216.
Prittie, J., 2004. Canine parvoviral enteritis: a review of diagnosis, management, and prevention. Journal of Veterinary Emergency and Critical Care 14, 167-176.
Proksch, A.L., Unterer, S., Truyen, U., Hartmann, K., 2014. Efficacy of the paramunity inducer PIND-ORF in the treatment of canine parvovirus infection. Vet J 202, 340-347.
Rizopoulos, D., Verbeke, G., Molenberghs, G., 2010. Multiple-imputation-based residuals and diagnostic plots for joint models of longitudinal and survival outcomes. Biometrics 66, 20-29.